Skip to Content

Posts tagged with "Pharmacokinetics"

  • Drug Development

    Heavy Atoms, Heavy Profits?

    Carbon 12, nitrogen 14 – for that matter, hydrogen 1. Everyone who’s had to study even a bit of chemistry has had to learn the molecular weights of the elements, figure molecular weights from formulas, and so on. But these numbers aren’t quite as round and even as they look, and the consequences of that… Read More
  • Book Recommendations

    A Med-Chem Book Recommendation

    As per the comments to the last post, this book, Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization, looks like a very nice overview of these issues for the practicing medicinal chemist. From what I’ve seen of it, there’s a lot of you-need-to-know-this information for people getting up to sp… Read More
  • Drug Development

    Prodrugs: How the Pros Do It?

    I’m going to write this morning about a question that actually came up among several of us at the train station this morning. I’m on a route that takes a lot of people into Cambridge, so we have a good proportion of pharma/biotech people on board. And today we got to talking about prodrugs: like… Read More
  • Clinical Trials

    Down The Chute in Phase III

    Here’s a good article over at the In Vivo Blog on this year’s crop of expensive Phase III failures. They’ve mostly been biotech drugs (vaccines and the like), but it’s a problem everywhere. As In Vivo‘s Chris Morrison puts it: Look, drugs fail. That happens because drug development is very difficult. Even Phase III dru… Read More
  • Drug Development

    Sticky Containers, Vanishing Drugs

    There’s no end to the variables that can kick your data around in drug discovery. If you concentrate completely on all the things that could go wrong, though, you’ll be too terrified to run any useful experiments. You have to push on, but stay alert. It’s like medical practice: most of the time you don’t… Read More
  • Academia (vs. Industry)

    Getting To Lyrica

    There’s an interesting article in Angewandte Chemie by Richard Silverman of Northwestern, on the discovery of Lyrica (pregabalin). It’s a rare example of a compound that came right out of academia to become a drug, but the rest of its story is both unusual and (in an odd way) typical. The drug is a very… Read More
  • Animal Testing

    The Animal Testing Hierarchy

    I’ve had some questions about animal models and testing, so I thought I’d go over the general picture. As far as I can tell, my experience has been pretty representative. There are plenty of animal models used in my line of work, but some of them you see more than others. Mice and rats are… Read More
  • Diabetes and Obesity

    Eat It, Breath It, Soak in It?

    After Pfizer’s Exubera inhaled-insulin product died so horribly in the market last year, the other companies working in the same space had to be worried. Lilly and Alkermes have had a long-running program, as has a smaller company called Mannkind. But recently, another contender, Novo Nordisk, has announced that they and partner Aradigm have deci… Read More
  • Drug Development

    Like Clockwork

    There are a lot of drug development issues that people outside the field (and beginning medicinal chemists) don’t think about. A significant one that sounds trivial is how often your wonder drug is going to be taken. Once a day is the standard, and it’s generally what we shoot for unless there’s some reason to… Read More
  • Life in the Drug Labs

    Sulfur, Your Pal. Mostly.

    I had a question the other day in my e-mail about various sulfur-containing functional groups in drugs. My answers, condensed, were as follows: Sulfides: will always be under suspicion for oxidation in vivo. If that’s your main mode of metabolism and clearance, though, then the problem can be manageable. Still, many people avoid them to… Read More
...8910